SCORE of Medication Error in Internal Medecin Unit (SCOREME)
2018年4月23日 更新者:University Hospital, Montpellier
Developpemment of a Score to Assess Risk of Medication Errors in Internal Medecin Unit
Transfers between interfaces of care are recognized as a source of medication discrepancies, medication errors (MEs) and potentially adverse drug events.
ME are very common at hospital and may have important clinical and economic consequences.
The lack and loss of medication information and communication between health professionals at points of care transition may often lead to ME.
According to the literature, up to two thirds of medication histories contain at least one error.
Some studies have compared pharmaceutical team with physician or nurse on the detection of UMD or ME and have reported that pharmacists were one of the best health care providers to establish medication history.
To improve medication safety and decrease MEs rate, several institutions have recommended to develop medication reconciliation at all transition points such as admission, transfer and discharge.
Medication reconciliation is the process that compares a patient's medication order to all medications that the patient has been taking and should take at admission, transfer and discharge of hospitalization.
Medication reconciliation programs led by pharmacists are effective to reduce medications discrepancies.
However, studies evaluating the efficacy of medication reconciliation program are very heterogeneous in terms of populations, definitions and methodology.
Thus, proportion of ME differs enormously between studies, ranging from under 10% to over 60% at admission of hospitalization.
Elderly patients with their numerous comorbidities associated with polypharmacy, such as patients of internal medecin unit, are at high risk of ME and at risk of safety issues.
However, medication reconciliation process is very time consuming with an average of 30 minutes by patient.
Thereby, review of all inpatients within 24 hours of admissions is very difficult or impossible.
Targeting "high-risk situation" and "high-risk patient" are crucial to detect ME before causing harm.
Therefore, evaluating the risk of MEs and their potential consequences in specific population of internal medicine unit using a validated medication reconciliation process seems of utmost importance for internal medicine specialist clinical practice and the decrease of ME rate.
Consequently, the aim of our study was to (i) evaluate the prevalence of ME in an internal medicine unit at admission of hospitalization, (ii) determine the type of medication involved and the potential clinical impact of ME and (iii) identify factors associated with a risk of ME and serious ME.
研究概览
地位
完全的
研究类型
观察性的
注册 (实际的)
1957
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Montpellier、法国、34295
- Uhmontpellier
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Study population was composed of patient hospitalized in internal medecine unit of Montpellier University hospital.
描述
Inclusion criteria:
- Patients aged above 18 years old, admitted to the department during the study period and hospitalized for at least 24 hours
Exclusion criteria:
- NA
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
People with at least one medication error
People with at least one medication error at hospital admission
|
Detection and correction of medication error at hospital admission
|
|
People without medication error at hospital admission
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
number of medication error
大体时间:1 day
|
number of medication error at hospital admission detected by clinical pharmacist during medication reconciliation process
|
1 day
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
number of variable associated to the risk of ME
大体时间:1 day
|
number of variable associated to the risk of ME detected by logistic regression analysis
|
1 day
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Cyril BREUKER、University Hospital, Montpellier
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2012年5月1日
初级完成 (实际的)
2017年11月1日
研究完成 (实际的)
2018年1月1日
研究注册日期
首次提交
2018年1月26日
首先提交符合 QC 标准的
2018年2月2日
首次发布 (实际的)
2018年2月5日
研究记录更新
最后更新发布 (实际的)
2018年4月24日
上次提交的符合 QC 标准的更新
2018年4月23日
最后验证
2018年2月1日
更多信息
与本研究相关的术语
其他研究编号
- RECHMPL18_0030
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
IPD 计划说明
NC
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.